The long-awaited preliminary results from the K-PAX Synergy Trial are out. While both the patient group and control groups showed improvements, the difference between the two was not statistically significant. The Synergy Trial was designed to produce an FDA-approvable treatment for Myalgic Encephalmyelitis/Chronic Fatigue Syndrome. The double-blinded, placebo-controlled trial evaluated the safety and efficacy of methylphenidate (generic Ritalin), combined with a mitochondrial support nutrient formula over 12 weeks. The outcome measurement tool used in the study was the Checklist Individual Strength (CIS), a patient-reported symptoms questionnaire specifically developed to evaluate CFS symptomatology.
Support nutrient has my interest more than Ritalin